1 paper3 findings
GLP-1 receptor agonists
downin humans1
GLP-1 receptor agonists protect against stroke or TIA in humans.
Humanspatients with T2DM and ASCVDmedian of 5.5 years60% malesn = 138,397
Stroke risk in diabetic patients with concomitant cardiovascular disease the CARDIAB-Stroke study
Annales d'endocrinologie17 Aug 2026
SGLT2 inhibitors
downin humans1
SGLT2 inhibitors protect against stroke or TIA in humans.
Humanspatients with T2DM and ASCVDmedian of 5.5 years60% malesn = 138,397
Stroke risk in diabetic patients with concomitant cardiovascular disease the CARDIAB-Stroke study
Annales d'endocrinologie17 Aug 2026
GLP-1 receptor agonists + SGLT2 inhibitors
downin humans1HR 0.78
GLP-1 receptor agonists + SGLT2 inhibitors lower the risk of stroke or TIA in humans (HR 0.78, 95% CI 0.75-0.81).
Humanspatients with T2DM and ASCVDmedian of 5.5 years60% malesn = 138,397
Stroke risk in diabetic patients with concomitant cardiovascular disease the CARDIAB-Stroke study
Annales d'endocrinologie17 Aug 2026
Among people with a brief stroke-like attack, 44 coronary heart disease events (81.5%) occurred more than 12 months later.Among people with a brief stroke-like attack, 44 coronary heart disease events (81.5%) occurred more than 12 months later.